IMPACT OF WHEY AND LEUCINE ON GLYCAEMIA IN ADULTS WITHOUT DIABETES_V2

  • Research type

    Research Study

  • Full title

    IMPACT OF WHEY AND LEUCINE ON GLYCAEMIA IN ADULTS WITHOUT DIABETES BUT WITH MODERATELY RAISED HbA1c (Whey2glo)

  • IRAS ID

    239941

  • Contact name

    Julie Lovegrove

  • Contact email

    j.a.lovegrove@reading.ac.uk

  • Sponsor organisation

    University of Reading

  • Duration of Study in the UK

    1 years, 11 months, 30 days

  • Research summary

    HIGHER THAN AVERAGE FASTING BLOOD SUGAR (GLUCOSE) IS A CHARACTERISTIC OF THOSE AT RISK OF DEVELOPING TYPE 2 DIABETES. AS A RESULT, THERE IS SIGNIFICANT INTEREST IN DIETARY FACTORS THAT COULD REDUCE LEVELS OF BLOOD GLUCOSE, LOWERING THE FREQUENCY OF THIS DISEASE IN THE POPULATION. EXISTING SCIENTIFIC EVIDENCE SUGGESTS AN IMPORTANT ROLE OF DAIRY PRODUCTS AND ESPECIALLY OF WHEY PROTEIN IN THE CONTROL OF BLOOD GLUCOSE LEVELS. HOWEVER, THERE IS A NEED FOR FURTHER STUDIES TO CONFIRM THESE FINDINGS IN A POPULATION WHICH HAVE HIGHER THAN AVERAGE FASTING BLOOD GLUCOSE LEVELS.

    THIS STUDY IS DESIGNED TO DETERMINE IF CONSUMING 50 G OF WHEY PROTEIN EVERY DAY FOR EIGHT WEEKS WILL HAVE MORE FAVOURABLE EFFECTS ON FASTING AND DAY-LONG GLYCAEMIA AND OTHER RISK FACTORS FOR DEVELOPING HEART DISEASE AND DIABETES COMPARED WITH WHEAT PROTEIN (50 G). WE WILL ALSO DETERMINE WHETHER THE AMINO ACID LEUCINE, FOUND IN HIGHER AMOUNTS IN WHEY PROTEIN, PLAYS AN IMPORTANT ROLE IN REGULATING BLOOD GLUCOSE LEVELS.

    IN THIS DOUBLE-BLIND, CONTROLLED 3-ARM CROSS-OVER DIETARY INTERVENTION STUDY, 40 PEOPLE (20 MEN/20 WOMEN), AGED 20-70 YEARS WITH HBA1C LEVELS JUST ABOVE THE POPULATION AVERAGE (AN INDICATOR OF HIGHER THAN AVERAGE BLOOD GLUCOSE LEVELS) WILL RECEIVE 3 DIFFERENT PROTEIN SUPPLEMENTS IN RANDOM ORDER FOR 8 WEEKS, WITH A 4-WEEK WASH-OUT PERIOD BETWEEN EACH PROTEIN SUPPLEMENT. AT THE BEGINNING AND END OF EACH PROTEIN PHASE, A FASTING BLOOD SAMPLE WILL BE COLLECTED TO EVALUATE THE LONG-TERM EFFECTS OF THE SPECIFIC PROTEINS ON BLOOD GLUCOSE AND INSULIN (PRIMARY OUTCOMES MEASURES) AND OTHER SECONDARY MARKERS OF HEART DISEASE AND TYPE 2 DIABETES RISK.

    At the BEGINNING of each protein intervention phase, a subgroup of participants (N=24) will also take part in a day-long study visit to DETERMINE the SHORT-TERM effects of the assigned protein INTERVENTION ON THE PRIMARY AND SECONDARY OUTCOME MEASURES.

  • REC name

    South Central - Hampshire A Research Ethics Committee

  • REC reference

    18/SC/0383

  • Date of REC Opinion

    1 Oct 2018

  • REC opinion

    Further Information Favourable Opinion